DNTH: Dianthus Therapeutics Inc Company Value to Net Income
The battle for patent priority in the field of rare pathologies creates high uncertainty, yet the P/E ratio of Dianthus Therapeutics (DNTH) on the GURU.Markets chart demonstrates the market's valuation of business viability, where the value settled at -25.80. Strict FDA oversight and capital-intensive R&D confirm this stability, while current income is based on partnership grants for the development of complement systems.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_DNTH_-_Dianthus-Therapeutics_-_PE-Multiple "DNTH: Dianthus Therapeutics Business Payback Period 02/21/2024 - 11/15/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Dianthus Corp (DNTH)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Dianthus Therapeutics|DNTH - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital dianthustx.com|DNTH - Company Debts|Debt to Book Value Ratio Dianthus Therapeutics Inc|DNTH - Company Long-Term Debts|Short-Term Debt Dianthus Therapeutics|Immediate Liquidity Ratio dianthustx.com
- earnings and market multiples details:
DNTH - Net Profit|Company Profit Forecast Dianthus Therapeutics|DNTH - P/E Multiple|Forward P/E Multiple Dianthus Corp|DNTH - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Dianthus Corp|DNTH - Operating profit before deduction of amortization|Earnings per share for the last four quarters Dianthus Therapeutics|DNTH - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months dianthustx.com|DNTH - Net earnings per share growth this year|Earnings growth forecast for next year Dianthus Therapeutics
- sales volume and revenue indicators:
Comprehensive company analysis:Dianthus Therapeutics, Inc. DNTH
For Dianthus Therapeutics (DNTH), where a young team is advancing early-stage clinical programs, the price-to-earnings dynamics reflect market expectations for the future success of the biotech syndicate. This multiple, calculated as the ratio of market capitalization to net income, allows investors to assess the premium paid for growth potential, avoiding emotional buying at peaks and recognizing the risk of stagnation when values are excessively low.
Key competitors
P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple PHVS (pharvaris.com)|AbCellera Bio (ABCL) - Market Cap to Earnings|TRML: Price to Earnings Ratio|Market Cap to Net Income PGEN|PHAR: P/E Multiple|Market Cap to Earnings Nektar Therapeutics Inc (NKTR)|Price to Earnings Ratio UPB|Price to Earnings Multiple ZBIO (Zenas Biopharma, Inc.)|Price to Earnings Ratio IMNM (Immunome Bio)|Business Payback Period Gossamer Bio, Inc.|P/E Multiple KALV (KalVista Pharma)|Septerna, Inc. (SEPN) - Market Cap to Earnings|PVLA - Price to Earnings Ratio|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|ANAB - Business Payback Period|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|Price to Earnings Ratio RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Company Value to Net Income|P/E Multiple ACRS (Aclaris Therapeutics)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX (Theratechnologies, Inc) - Price to Earnings Ratio|AVTX (Avalo Therapeutics, Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals|Price to Earnings Ratio Agenus Inc. (AGEN)|Price to Earnings Ratio Climb Bio Inc. CLYM|P/E Multiple ZURA (Zura Bio Ltd)|ATYR - Price to Earnings Ratio|ADAG - Price to Earnings Ratio|IMA - P/E Multiple|STTK: P/E Multiple|Equillium Bio (EQ) - P/E Multiple|CNTB (connectbiopharm.com) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Market Cap to Net Income|P/E Multiple adicetbio.com ACET|Celularity - P/E Multiple|Company Value to Net Income INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Price to Earnings Ratio|Market Cap to Net Income KZR (Kezar Life Sciences)|Price to Earnings Ratio SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Market Cap to Net Income|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple
